source
- Novartis shares tumble after late-stage failure of Avidity-acquired drugNovartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…
- Benelux’s strong science base eyed for biotech scaling despite funding gapsBelgium and the Netherlands have built some of Europe’s strongest life‑science ecosystems, anchored by leading research institutions and a growing pool of biotech talent. Early‑stage capital remai…